Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:22:49.829Z.
Calculation as of: 2026-10-06T17:22:49.829Z.
Quote observation: 2026-10-06T17:20:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8656b7a9da6ad27e4e3bee00a1f051c5b9ad9ad1f17b43070ca9e23e03b297bf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$407.34M
Price/FCF Ratio
N/A
TTM Avg
6.66
3Y Avg
6.66
5Y Avg
6.66
Market Cap
$403.87M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$409.70M
Price/FCF Ratio
N/A
TTM Avg
198.72
3Y Avg
198.72
5Y Avg
198.72
Market Cap
$411.33M
Price/FCF Ratio
N/A
TTM Avg
44.26
3Y Avg
44.26
5Y Avg
44.26
Market Cap
$413.54M
Price/FCF Ratio
N/A
TTM Avg
4285.33
3Y Avg
985.66
5Y Avg
501.76
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurogene Inc. (NGNE) | $406.04M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $406.41M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $407.34M | N/A | 6.66 | 6.66 | 6.66 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $403.87M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $408.54M | N/A | N/A | N/A | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $409.70M | N/A | 198.72 | 198.72 | 198.72 |
| Prothena Corporation plc (PRTA)vs › | $411.33M | N/A | 44.26 | 44.26 | 44.26 |
| Rezolute, Inc. (RZLT)vs › | $409.72M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $413.54M | N/A | 4285.33 | 985.66 | 501.76 |
| Senseonics Holdings, Inc. (SENS)vs › | $418.99M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
